AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04390035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction using Delfi Personalized Tourniquet System
Description: Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
Study NCT02287506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimised Diagnostic Strategy
Description: (ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
Study NCT02307188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constellation Full Contact Mapping Catheter
Description: 64-electrode intracardiac mapping catheter.
Study NCT00734617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Groups 1 \& 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 \& 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day
Study NCT05094986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Medication Adherence (IMA) Intervention
Description: The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.
Study NCT05094986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.
Study NCT02198755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hitachi-Aloka Noblus ultrasound scanner
Description: High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
Study NCT02198755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI with or without contrast
Study NCT03406832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroprusside Sodium
Description: Intracoronary infusion 50\~100μg each time (repeated)
Study NCT03406832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Hydrochloride
Description: Intracoronary infusion 10μg/kg for single time
Study NCT03406832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparinized saline
Description: Intracoronary infusion 2ml for single time
Study NCT02460315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early cholecystectomy
Description: Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
Study NCT02460315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: late cholecystectomy
Description: Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
Study NCT02120859 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FFR - guided DEB angioplasty
Description: DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR > 0.8.
Study NCT02120859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR - guided DEB angioplasty
Description: DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR > 0.8.
Study NCT02120859 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Provisional bare metal stenting
Description: In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
Study NCT00842894 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Safety and effectiveness data collection in connection with the use of the drug.
Study NCT00842894 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
Study NCT05114018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized A. muciniphila
Description: Daily oral dose
Study NCT05114018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo = identical to verum regarding the form, size, taste, color and intake
Study NCT00291330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate 150 mg
Description: twice daily
Study NCT00291330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin (INR 2-3)
Description: prn to maintain INR (2-3)
Study NCT04822428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation
Description: Osteopathic manipulative techniques including; suboccipital release technique,sacral release technique, diaphragmatic release, mesentery release, and Colonic manipulation
Study NCT03849079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyponut
Description: Prick tests with hyponut
Study NCT03233373 — intervention group
Intervention type: DEVICE
Intervention: Seek CompactPro thermal imager
Description: A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
Study NCT01445873 — intervention group
Intervention type: DRUG
Intervention: Sitaxentan sodium
Description: Sitaxentan sodium 100 mg / day
Study NCT02754180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
Study NCT02754180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
Study NCT02754180 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TS-1 with radiation
Description: gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
Study NCT05103488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care
Description: CPC is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach.
Study NCT05103488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
Study NCT01963221 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: fludeoxyglucose(18f)
Study NCT01963221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Study NCT01963221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cardiac and aortic magnetic resonance imaging
Study NCT01963221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: carotid femoral pulse wave velocity
Study NCT01963221 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: positron emission tomography
Study NCT01963221 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: computed tomography
Study NCT01841398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia Lifestyle Improvement
Description: * Goal setting to improve diet, physical activity or smoking behaviours~* Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.
Study NCT01841398 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
Study NCT02717936 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immunohistochemistry using Pancytokeratin Staining
Study NCT02623309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic (Allo) hematopoietic stem cell transplantation
Study NCT02623309 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic (Allo) hematopoietic stem cell transplantation
Study NCT03663205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study NCT03663205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously
Study NCT03663205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously
Study NCT03663205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously
Study NCT03663205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously
Study NCT03579979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.
Study NCT03579979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Midazolam 0.7mg/kg 45 min before surgery
Description: Inj . Midazolam 0.7 mg/kg given as premedication.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Midazolam 0.7mg/kg 45 min before surgery
Description: Inj . Midazolam 0.7 mg/kg given as premedication.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Propofol 2.5mg/kg
Description: It was given to induce anesthesia after 3 min of pre oxygenation.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Propofol 2.5mg/kg
Description: It was given to induce anesthesia after 3 min of pre oxygenation.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Atracurium 0.5 mg/kg
Description: It was given to induce muscle relaxation during anesthesia.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Atracurium 0.5 mg/kg
Description: It was given to induce muscle relaxation during anesthesia.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane 2.5 vol %
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2.5 vol %
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Cefuroxime 1.5 g IV
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Cefuroxime 1.5 g IV
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Ketorolac 30 mg IV
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
Study NCT03663205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously
Study NCT03663205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously
Study NCT03593772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mission Reconnect
Description: This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
Study NCT03593772 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mission Reconnect
Description: This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
Study NCT03284866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03284866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03284866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study NCT03284866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given IM
Study NCT01048268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucose-dependent insulinotropic polypeptide
Description: For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight
Study NCT01048268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: copy GIP infusion rates
Study NCT02577900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acticoat absorbent
Description: Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
Study NCT02577900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Honey gel sheet
Description: Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
Study NCT02577900 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jelonet
Description: Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
Study NCT05117866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel Monotherapy
Description: Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
Study NCT04542330 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Denmark
Description: Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.
Study NCT04542330 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
Study NCT04580472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
Study NCT04580472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
Study NCT04058600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Software
Description: Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
Study NCT03599843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
Study NCT01682512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500
Study NCT01682512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan®
Study NCT01682512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera®
Study NCT04583631 — intervention group
Intervention type: PROCEDURE
Intervention: Adenoidectomy surgery
Description: All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
Study NCT04181216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomically aligned total knee arthroplasty implant
Description: In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
Study NCT04181216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically aligned total knee arthroplasty implant
Description: In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
Study NCT01578343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat
Description: 1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation
Study NCT02203188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lid debridgement scaling
Study NCT06545448 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention (PCI)
Description: A percutaneous coronary intervention (PCI) is a minimally invasive procedure to open blocked coronary (heart) arteries. An older name for PCI is coronary angioplasty with stenting or angioplasty for short.
Study NCT04643054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ovotransferrin
Description: Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days